<PRE>
[Federal Register: February 22, 2002 (Volume 67, Number 36)]
[Notices]               
[Page 8272]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr22fe02-68]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS-3087-N]

 
Medicare Program; Meeting of the Executive Committee of the 
Medicare Coverage Advisory Committee--April 16, 2002

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces a public meeting of the Executive 
Committee (the Committee) of the Medicare Coverage Advisory Committee 
(MCAC). The Committee provides advice and recommendations to us about 
clinical issues. The Committee will act upon recommendations from the 
Diagnostic Imaging Panel of the MCAC regarding whether and when it is 
scientifically justified to use FDG Positron Emission Tomography or 
other neuroimaging devices for the diagnosis and patient management of 
those with Alzheimer's disease.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. App. 2, section 10(a)(1) and (a)(2)).

DATES: The Meeting: April 16, 2002 from 8 a.m. until 4:30 p.m., E.D.T.
    Deadline for Presentations and Comments: March 27, 2002, 5 p.m., 
E.D.T.
    Special Accommodations: Persons attending the meeting who are 
hearing or visually impaired, or have a condition that requires special 
assistance or accommodations, are asked to notify the Executive 
Secretary by March 18, 2002 (see FOR FURTHER INFORMATION CONTACT).

ADDRESSES: The Meeting: The meeting will be held at the Baltimore 
Convention Center, Room 321-322, One West Pratt Street, Baltimore, MD 
21201.
    Presentations and Comments: Submit formal presentations and written 
comments to Janet A. Anderson, Executive Secretary; Office of Clinical 
Standards and Quality; Centers for Medicare & Medicaid Services; 7500 
Security Boulevard; Mail Stop C1-09-06; Baltimore, MD 21244.
    Website: You may access up-to-date information on this meeting at 
<A HREF="http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.hcfa.gov/coverage">www.hcfa.gov/coverage</A>.
    Hotline: You may access up-to-date information on this meeting on 
the CMS Advisory Committee Information Hotline, 1-877-449-5659 (toll 
free) or in the Baltimore area (410) 786-9379.

FOR FURTHER INFORMATION CONTACT: Janet A. Anderson, Executive 
Secretary, 410-786-2700.

SUPPLEMENTARY INFORMATION: On December 14, 1998, we published a notice 
in the Federal Register (63 FR 68780) to describe the Medicare Coverage 
Advisory Committee (MCAC), which provides advice and recommendations to 
us about clinical issues. This notice announces the following April 16, 
2002 public meeting of the Executive Committee (the Committee) of the 
MCAC.

Current Panel Members

    Harold C. Sox, M.D.; Daisy Alford-Smith, Ph.D.; Wade Aubry, M.D.; 
Linda Bergthold, Ph.D.; Ronald M. Davis, M.D.; John H. Ferguson, M.D.; 
Leslie P. Francis, J.D., Ph.D.; Alan M. Garber, M.D., Ph.D.; Thomas V. 
Holohan, M.D., M.A.; Michael D. Maves, M.D., M.B.A.; Barbara J. McNeil, 
M.D., Ph.D.; Robert L. Murray, Ph.D.; Frank J. Papatheofanis, M.D., 
Ph.D.; Randel E. Richner, M.P.H.

Meeting Topic

    The Committee will act on recommendations from the Diagnostic 
Imaging Panel of the MCAC regarding FDG Positron Emission Tomography 
imaging for Alzheimer's disease, mild cognitive impairment, and 
dementia.

Procedure and Agenda

    This meeting is open to the public. The Committee will hear oral 
presentations from the public for approximately 90 minutes. The 
Committee may limit the number and duration of oral presentations to 
the time available. If you wish to make a formal presentation, you must 
notify the Executive Secretary named in the FOR FURTHER INFORMATION 
CONTACT section of this notice, and submit the following by the 
Deadline for Presentations and Comments date listed in the DATES 
section of this notice: a brief statement of the general nature of the 
evidence or arguments you wish to present, and the names and addresses 
of proposed participants. A written copy of your presentation must be 
provided to the Executive Secretary before offering your public 
comments. We will request that you declare at the meeting whether or 
not you have any financial involvement with manufacturers of any items 
or services being discussed (or with their competitors).
    After the public and CMS presentations, the Committee will 
deliberate openly on the topic. Interested persons may observe the 
deliberations, but the Committee will not hear further comments during 
this time except at the request of the chairperson. The Committee will 
also allow approximately a 30-minute open public session for any 
attendee to address issues specific to the topic. At the conclusion of 
the day, the members will vote, and the Committee will make its 
recommendation.

    Authority: 5 U.S.C. App. 2, section 10(a)(1) and (a)(2).

(Catalog of Federal Domestic Assistance Program No. 93.774, 
Medicare--Supplementary Medical Insurance Program)

    Dated: January 31, 2002.
Jeffrey L. Kang,
Director, Office of Clinical Standards and, Quality, Centers for 
Medicare & Medicaid Services.
[FR Doc. 02-3986 Filed 2-21-02; 8:45 am]
BILLING CODE 4120-01-P

</PRE>